Replimune Group’s (REPL) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright also issued estimates for Replimune Group’s Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.93) EPS.

Several other brokerages have also recently issued reports on REPL. Roth Mkm assumed coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. JPMorgan Chase & Co. lifted their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Finally, Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group has an average rating of “Buy” and an average price target of $16.80.

Replimune Group Stock Down 5.3 %

Shares of Replimune Group stock opened at $10.80 on Tuesday. The business’s fifty day moving average price is $11.46 and its two-hundred day moving average price is $9.54. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 13.46. The company has a market capitalization of $738.94 million, a P/E ratio of -3.54 and a beta of 1.19. Replimune Group has a 1-year low of $4.92 and a 1-year high of $12.97.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, research analysts forecast that Replimune Group will post -3.05 EPS for the current year.

Institutional Trading of Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of REPL. Nisa Investment Advisors LLC boosted its position in shares of Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the period. Point72 DIFC Ltd acquired a new stake in shares of Replimune Group in the second quarter worth $57,000. Arizona State Retirement System acquired a new stake in shares of Replimune Group in the second quarter worth $108,000. Quest Partners LLC boosted its position in shares of Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares during the period. Finally, Erste Asset Management GmbH acquired a new stake in shares of Replimune Group in the third quarter worth $133,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.